0 CHECKOUT

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015

  • ID: 3500413
  • October 2015
  • 128 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Eli Lilly and Company
  • Humanetics Corporation
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • MORE

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015

Summary

The report ‘Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2015’, provides an overview of the Post-Traumatic Stress Disorder (PTSD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD) and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Addex Therapeutics Ltd
  • Eli Lilly and Company
  • Humanetics Corporation
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Post-Traumatic Stress Disorder (PTSD) Overview

Therapeutics Development

Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview

Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis

Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies

Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes

Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies

Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes

Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development

Addex Therapeutics Ltd

Azevan Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc.

Eli Lilly and Company

HolsboerMaschmeyer NeuroChemie GmbH

Humanetics Corporation

Intra-Cellular Therapies, Inc.

Marinus Pharmaceuticals, Inc.

Neuralstem, Inc.

Neurocrine Biosciences, Inc.

NeuroNascent, Inc.

Omeros Corporation

Otsuka Holdings Co., Ltd.

Pfizer Inc.

Polleo Pharma Limited

Synchroneuron Inc.

Tonix Pharmaceuticals Holding Corp.

Vanda Pharmaceuticals Inc.

Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

acamprosate calcium SR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADX-71743 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AM-3506 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brexpiprazole - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug for Post-Traumatic Stress Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Inhibit FAAH for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drugs to Modulate NPSR for Anxiety Disorder - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ganaxolone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HL-9001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

IC-87201 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

iloperidone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ITI-007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NNI-351 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NSI-189 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-04457845 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Rycal - Drug Profile

Product Description

Mechanism of Action

R&D Progress

S-107 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target GPR151 for CNS Diseases - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Post-Traumatic Stress Disorder - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SRX-246 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TNX-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Vaccine for Post-Traumatic Stress Disorder and Depression - Drug Profile

Product Description

Mechanism of Action

R&D Progress

verucerfont - Drug Profile

Product Description

Mechanism of Action

R&D Progress

vigabatrin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ZL-006 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Post-Traumatic Stress Disorder (PTSD) - Recent Pipeline Updates

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products

Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones

Featured News & Press Releases

Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium

May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR

May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry

Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder

Jun 10, 2014: Tonix Pharmaceuticals Receives IND Clearance From U.S. Food and Drug Administration for TNX-102 SL in Post-Traumatic Stress Disorder

Oct 11, 2013: Tonix Pharmaceuticals to Participate in the Women's Healthcare Innovation and Leadership Showcase on October 15, 2013

Aug 19, 2013: Tonix Pharmaceuticals Presents Nonclinical Results at the Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome

Oct 24, 2012: Tonix Pharma Completes Pre-IND Meeting With FDA For Potential New Treatment For Post-Traumatic Stress Disorder

Oct 15, 2012: Indiana University Scientists Identify New Compound That Could Prevent Post-Traumatic Stress Disorder

Oct 15, 2012: Indiana University Scientists Discover New Drug For Preventing Post-Traumatic Stress Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2015

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Comparative Analysis by Unknown Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by HolsboerMaschmeyer NeuroChemie GmbH, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurocrine Biosciences, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pfizer Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2015

Post-Traumatic Stress Disorder (PTSD) - Pipeline by Vanda Pharmaceuticals Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Post-Traumatic Stress Disorder (PTSD) Therapeutics - Recent Pipeline Updates, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2015

Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2015

Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Addex Therapeutics Ltd
Azevan Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Eli Lilly and Company
HolsboerMaschmeyer NeuroChemie GmbH
Humanetics Corporation
Intra-Cellular Therapies, Inc.
Marinus Pharmaceuticals, Inc.
Neuralstem, Inc.
Neurocrine Biosciences, Inc.
NeuroNascent, Inc.
Omeros Corporation
Otsuka Holdings Co., Ltd.
Pfizer Inc.
Polleo Pharma Limited
Synchroneuron Inc.
Tonix Pharmaceuticals Holding Corp.
Vanda Pharmaceuticals Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Pfizer Inc.
  • Grünenthal GmbH
  • GlaxoSmithKline PLC
  • Abbott Laboratories Ltd.
  • Roche Diagnostics Ltd.
  • Novo Nordisk A/S